Gain Bayer 4th trim suffers from weak chemical business
LEVERKUSEN, Germany (Reuters) – the quarterly profit Bayer, the pharmaceutical main Germany, failed with the expectations because of the low sales volumes in its chemical Division, but the firm is confident in the launches of new drugs to improve their performance in the next few years. Adjusted profit for the fourth quarter before interest, taxes, depreciation and amortization (EBITDA) for the Group dropped a 8.8% to 1540 million euros (2,060 million dollars), under the average estimate of 1,620 $ billion in a Reuters poll. The group, leading manufacturer MaterialScience unit world of transparent plastics and foam chemicals for lights of cars and sports eyewear, suffered a fall from a 64 by % of its profit for the fourth quarter by the rise of the prices of raw materials. On Tuesday, the group said that it expected a slight increase of its EBITDA adjusted this year, with a rise in sales of around 3 percent, adjusted for variations foreign exchange and acquisitions. Bayer has said that its most promising drugs, headed by the anti-clotting pill Xarelto, have a maximum combined annual sales potential that skirts the €5 billion, but that this year is they notice very little. Market research has shown that Xarelto had a starting slow in comparison with its rival Pradaxa, Boehringer Ingelheim, affecting market expectations of a a 3.2 percent advance in the EBITDA adjusted Group for...
Read More